Dyne Therapeutics, Inc. (DYN)

NMS – Real vaqt narxi. Valyuta: USD

18.37

-0.09 (-0.49%)

Yopilishda: May 12, 2026, 4:00 PM EDT

18.31

-0.06 (-0.33%)

Bozor oldidan: May 13, 2026, 7:27 AM EDT

11.05.2026

Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know

Dyne Therapeutics (DYN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11.05.2026

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 -

27.04.2026

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier -

23.04.2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 18 new employees. The awards were made as an inducement material to the new employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

01.04.2026

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care experts -

09.03.2026

Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

09.03.2026

Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case

Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating expenses in 2025. Encouraging long-term cardiopulmonary data from the DELIVER trial of z-rostudirsen (DYNE-251) strengthens the bull case for DMD therapy. Initiation of the pivotal Phase 3 HARMONIA trial for DYNE-101 in DM1 marks a critical regulatory and value inflection point.

Videolar

No Data

There is no data to display

Press-relizlar

11.05.2026

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 -

27.04.2026

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier -

23.04.2026

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01.04.2026

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Dyne Therapeutics, Inc. (DYN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Dyne Therapeutics, Inc. (DYN)

Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case

Videolar

No Data

Press-relizlar

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case

Videolar

No Data

Press-relizlar

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Search stocks

Dyne Therapeutics, Inc. (DYN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Dyne Therapeutics, Inc. (DYN)

Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case

Videolar

No Data

Press-relizlar

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Dyne Therapeutics, Inc. (DYN) Presents at TD Cowen 46th Annual Health Care Conference Prepared Remarks Transcript

Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case

Videolar

No Data

Press-relizlar

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines